Crossmark

Derivation of two iPSC lines (KAIMRCi004-A, KAIMRCi004-B) from a Saudi patient with Biotin-Thiamine-responsive Basal Ganglia Disease (BTBGD) carrying homozygous pathogenic missense variant in the SCL19A3 gene

Crossref DOI link: https://doi.org/10.1007/s13577-024-01097-4

Published Online: 2024-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alowaysi, Maryam

Baadhaim, Moayad

Al-Shehri, Mohammad

Alzahrani, Hajar

Badkok, Amani

Attas, Hanouf

Zakri, Samer

Alameer, Seham

Malibari, Dalal

Hosawi, Manal

Daghestani, Mustafa

Al-Ghamdi, Khalid

muharraq, Mohammed

Zia, Asima

Tegne, Jesper

Alfadhel, Majid

Aboalola, Doaa

Alsayegh, Khaled https://orcid.org/0000-0003-2654-835X
Funding

Funding for this research was provided by:

Pfizer Pharmaceuticals (NRJ22/060/03)

King Abdullah International Medical Research Center (NRJ22J/005/01)
License Information

Text and Data Mining valid from 2024-07-09

Version of Record valid from 2024-07-09
More Information

Article History

Received: 28 February 2024

Accepted: 27 June 2024

First Online: 9 July 2024

Declarations

:

: The authors declare that they have no conflict of interest.

: This study was approved by the Institutional Review Board of the Ministry of National Guard Health Affairs (Protocol# NRJ22J/005/01 and NRJ22J/060/30).

: Written informed consent was obtained from the study subjects.

Document is current

Any future updates will be listed below